Straumann Group (STMN) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
19 Aug, 2026Executive summary
CEO to step down at year-end after 20 years, with Christopher Norbye appointed as successor, ensuring a smooth handover and continuity of strategy.
H1 2026 revenue reached CHF 1.4 billion, with Q2 organic growth of 8.5% and H1 organic growth of 7.8%.
Strong operational leverage from manufacturing productivity, supply chain optimization, and disciplined OPEX management.
Digital solutions, especially IOS, SIRIOS X3, and iEXCEL, drove double-digit revenue growth and market share gains.
Premium implantology, digital solutions, and orthodontics were key growth drivers, with Neodent's global expansion contributing.
Financial highlights
Q2 revenue reached CHF 707 million, bringing H1 revenue to CHF 1.4 billion (organic growth 7.8%, reported 2.3%).
Core EBIT margin improved to 26.9% at constant 2025 FX, or 25.7% including currency effects, up 90 bps year-over-year.
Core gross profit was CHF 972 million (core gross margin 70.5%); IFRS gross margin was 72.0%.
Core net profit reached CHF 262 million (margin 19%), up 15.7% year-over-year; IFRS net profit margin was 18.2%.
Free cash flow increased 49% to CHF 169 million (12.2% of net revenue); CAPEX was CHF 74 million (5.4% of revenue), down from CHF 113 million prior year.
Outlook and guidance
Upgraded full-year 2026 guidance: high single-digit organic revenue growth and core EBIT margin improvement of 140–170 basis points at constant 2025 FX.
2030 margin ambition remains unchanged, with sustainable improvements expected to continue.
Profitability improvement expected to be evenly distributed between H1 and H2 2026.
Confident in ability to deliver midterm guidance, supported by management alignment and strong execution.
Significant growth opportunities in a CHF 20bn+ addressable market.
Latest events from Straumann Group
- Q1 2026 organic revenue grew 7.1%, with robust regional and segment momentum.STMN
Q1 2026 - 8.9% organic revenue growth, strong margins, and digital-driven innovation in 2025.STMN
Q4 2025 - Targets 10% CAGR revenue and margin expansion by 2030 through digital innovation and operational excellence.STMN
CMD 2025 - Q3 organic revenue rose 8.3%, with strong EMEA/LATAM growth and a confirmed positive outlook.STMN
Q3 2025 - 10.2% organic revenue growth and robust digital momentum drive strong H1 2025 results.STMN
Q2 2025 - Q3 organic revenue rose 11.2% to CHF 585.5–586M, with 2024 outlook for double-digit growth confirmed.STMN
Q3 2024 - Strong H1 2024 organic growth and digital focus drive upgraded outlook after DrSmile divestiture.STMN
Q2 2024 - Q1 2025 delivered 11% organic growth, led by APAC, EMEA, and digital innovation, with outlook confirmed.STMN
Q1 2025 - 13.7% organic revenue growth to CHF 2.5B, strong global gains, and higher dividend proposed.STMN
Q4 2024